---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-128310"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2022-12-19T23:59:59+00:00"
generated_at: "2026-06-21T02:22:06.879075+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Onconova adds two independent directors with pharma R&D backgrounds

## Summary
- Board expanded to eight; elected Peter Atadja (former Novartis Executive Director) and Trafford Clarke (former Eli Lilly Managing Director).
- Atadja appointed Chair of Nominating & Corporate Governance; Clarke joins Compensation Committee.
- Each receives standard non-employee director compensation plus one-time option to purchase 100,000 shares of common stock.
- Atadja led discovery/development of first approved HDAC inhibitor (FARYDAK); Clarke spent 31 years at Eli Lilly in senior R&D roles.

## SEC filing metadata
- accession: 0001104659-22-128310
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2022-12-19T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465922128310/0001104659-22-128310-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465922128310/tm2233068d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-128310
- JSON: https://secwatch.observer/filing/0001104659-22-128310.json
- Plain text: https://secwatch.observer/filing/0001104659-22-128310.txt

## Key facts
- Executive change
  Trafford Clarke was elected as Director at Traws Pharma, Inc..
  - Action: elected
  - Role: Director
  source text: elected Peter Atadja, Ph.D. and Trafford Clarke, Ph.D. as members of the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130598/000110465922128310/0001104659-22-128310-index.htm
- Executive change
  Peter Atadja was elected as Director at Traws Pharma, Inc..
  - Action: elected
  - Role: Director
  source text: elected Peter Atadja, Ph.D. and Trafford Clarke, Ph.D. as members of the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130598/000110465922128310/0001104659-22-128310-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.